| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 159 | 2024 | 541 | 33.250 |
Why?
|
| Tissue and Organ Procurement | 59 | 2023 | 228 | 15.690 |
Why?
|
| Kidney Failure, Chronic | 64 | 2023 | 489 | 11.030 |
Why?
|
| Waiting Lists | 56 | 2024 | 211 | 10.600 |
Why?
|
| Tissue Donors | 52 | 2024 | 316 | 9.690 |
Why?
|
| Graft Survival | 63 | 2023 | 446 | 7.830 |
Why?
|
| Living Donors | 51 | 2024 | 270 | 6.780 |
Why?
|
| Organ Transplantation | 13 | 2023 | 159 | 4.570 |
Why?
|
| Transplant Recipients | 19 | 2024 | 140 | 4.420 |
Why?
|
| Registries | 58 | 2024 | 1768 | 4.040 |
Why?
|
| Renal Dialysis | 35 | 2023 | 374 | 4.010 |
Why?
|
| Renal Insufficiency, Chronic | 33 | 2023 | 486 | 3.730 |
Why?
|
| Graft Rejection | 33 | 2023 | 513 | 3.500 |
Why?
|
| United States | 106 | 2024 | 12181 | 3.140 |
Why?
|
| Quality Indicators, Health Care | 9 | 2018 | 287 | 3.070 |
Why?
|
| Lung Transplantation | 7 | 2023 | 246 | 3.060 |
Why?
|
| Heart Transplantation | 8 | 2023 | 665 | 2.970 |
Why?
|
| Transplants | 10 | 2022 | 36 | 2.930 |
Why?
|
| Liver Transplantation | 13 | 2023 | 707 | 2.880 |
Why?
|
| Kidney | 33 | 2023 | 1188 | 2.660 |
Why?
|
| Humans | 313 | 2024 | 114662 | 2.490 |
Why?
|
| Middle Aged | 149 | 2021 | 26733 | 2.250 |
Why?
|
| Donor Selection | 13 | 2023 | 66 | 2.120 |
Why?
|
| Glomerular Filtration Rate | 31 | 2023 | 604 | 2.090 |
Why?
|
| Male | 187 | 2023 | 55583 | 2.000 |
Why?
|
| Adult | 131 | 2024 | 30544 | 1.960 |
Why?
|
| Aged | 114 | 2023 | 19069 | 1.930 |
Why?
|
| Risk Factors | 71 | 2023 | 8632 | 1.910 |
Why?
|
| Patient Selection | 9 | 2018 | 641 | 1.880 |
Why?
|
| Female | 179 | 2023 | 59493 | 1.750 |
Why?
|
| Program Evaluation | 8 | 2021 | 822 | 1.730 |
Why?
|
| Healthcare Disparities | 11 | 2023 | 480 | 1.700 |
Why?
|
| Delayed Graft Function | 8 | 2023 | 26 | 1.650 |
Why?
|
| Medicare | 12 | 2023 | 665 | 1.640 |
Why?
|
| Time Factors | 47 | 2022 | 6114 | 1.550 |
Why?
|
| Heart Failure | 9 | 2023 | 1945 | 1.530 |
Why?
|
| Transplantation | 4 | 2023 | 23 | 1.530 |
Why?
|
| Retrospective Studies | 70 | 2024 | 12546 | 1.530 |
Why?
|
| Travel | 4 | 2020 | 121 | 1.510 |
Why?
|
| Proportional Hazards Models | 33 | 2023 | 1075 | 1.510 |
Why?
|
| Health Services Accessibility | 11 | 2021 | 762 | 1.510 |
Why?
|
| Postoperative Complications | 18 | 2022 | 2128 | 1.500 |
Why?
|
| Nephrectomy | 11 | 2021 | 150 | 1.460 |
Why?
|
| Treatment Outcome | 58 | 2021 | 9088 | 1.440 |
Why?
|
| Acute Kidney Injury | 12 | 2023 | 637 | 1.350 |
Why?
|
| Patient Readmission | 6 | 2023 | 610 | 1.320 |
Why?
|
| Kidney Diseases | 11 | 2017 | 350 | 1.270 |
Why?
|
| Mycophenolic Acid | 9 | 2020 | 77 | 1.210 |
Why?
|
| Risk Assessment | 29 | 2022 | 2968 | 1.190 |
Why?
|
| Immunosuppressive Agents | 19 | 2020 | 646 | 1.190 |
Why?
|
| Social Class | 2 | 2021 | 204 | 1.180 |
Why?
|
| Resource Allocation | 2 | 2018 | 37 | 1.070 |
Why?
|
| Follow-Up Studies | 32 | 2022 | 4411 | 1.060 |
Why?
|
| Mortality | 5 | 2019 | 287 | 1.060 |
Why?
|
| Hospitals, Low-Volume | 2 | 2017 | 22 | 1.040 |
Why?
|
| Hospitals, High-Volume | 2 | 2017 | 39 | 1.030 |
Why?
|
| Young Adult | 37 | 2021 | 10466 | 1.010 |
Why?
|
| Prognosis | 26 | 2023 | 3329 | 1.010 |
Why?
|
| Adolescent | 49 | 2023 | 17841 | 1.000 |
Why?
|
| Surgicenters | 2 | 2016 | 6 | 1.000 |
Why?
|
| Body Mass Index | 13 | 2021 | 1958 | 0.990 |
Why?
|
| Organ Preservation | 3 | 2011 | 64 | 0.990 |
Why?
|
| Tacrolimus | 7 | 2013 | 134 | 0.960 |
Why?
|
| Life Expectancy | 2 | 2018 | 51 | 0.910 |
Why?
|
| Electronic Health Records | 12 | 2021 | 800 | 0.900 |
Why?
|
| Solitary Kidney | 1 | 2023 | 7 | 0.890 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2021 | 811 | 0.890 |
Why?
|
| Hospital Records | 2 | 2013 | 11 | 0.880 |
Why?
|
| Health Expenditures | 5 | 2020 | 171 | 0.870 |
Why?
|
| Cold Ischemia | 4 | 2011 | 27 | 0.860 |
Why?
|
| Health Policy | 5 | 2016 | 334 | 0.810 |
Why?
|
| Survival Rate | 18 | 2023 | 1644 | 0.790 |
Why?
|
| Cardiovascular Diseases | 6 | 2022 | 1727 | 0.780 |
Why?
|
| Quality Improvement | 3 | 2019 | 950 | 0.770 |
Why?
|
| Benchmarking | 2 | 2021 | 161 | 0.770 |
Why?
|
| Nephrology | 3 | 2021 | 48 | 0.770 |
Why?
|
| Tissue and Organ Harvesting | 6 | 2019 | 62 | 0.730 |
Why?
|
| Health Facilities | 3 | 2018 | 72 | 0.730 |
Why?
|
| Nutrition Surveys | 4 | 2016 | 224 | 0.720 |
Why?
|
| Cadaver | 9 | 2019 | 299 | 0.710 |
Why?
|
| Hospital Mortality | 7 | 2020 | 776 | 0.710 |
Why?
|
| Renal Insufficiency | 5 | 2018 | 137 | 0.700 |
Why?
|
| Aged, 80 and over | 33 | 2020 | 6345 | 0.700 |
Why?
|
| Pancreas Transplantation | 9 | 2014 | 61 | 0.700 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 58 | 0.690 |
Why?
|
| Hospitalization | 11 | 2023 | 1751 | 0.670 |
Why?
|
| Kidney Calculi | 4 | 2021 | 30 | 0.670 |
Why?
|
| Cohort Studies | 24 | 2023 | 4895 | 0.670 |
Why?
|
| Reoperation | 5 | 2015 | 514 | 0.650 |
Why?
|
| Ohio | 13 | 2018 | 135 | 0.650 |
Why?
|
| Emergency Service, Hospital | 11 | 2022 | 1815 | 0.630 |
Why?
|
| Residence Characteristics | 2 | 2022 | 275 | 0.620 |
Why?
|
| Quality Assurance, Health Care | 4 | 2019 | 311 | 0.610 |
Why?
|
| Cause of Death | 10 | 2021 | 361 | 0.600 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2015 | 64 | 0.600 |
Why?
|
| Decision Making | 3 | 2019 | 782 | 0.590 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2017 | 228 | 0.580 |
Why?
|
| BK Virus | 4 | 2014 | 14 | 0.570 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 207 | 0.570 |
Why?
|
| Weight Loss | 4 | 2013 | 642 | 0.570 |
Why?
|
| Population Health | 1 | 2018 | 42 | 0.570 |
Why?
|
| Polyomavirus Infections | 4 | 2014 | 22 | 0.560 |
Why?
|
| Tumor Virus Infections | 4 | 2014 | 43 | 0.560 |
Why?
|
| Hospitals | 4 | 2020 | 581 | 0.560 |
Why?
|
| Patient Discharge | 3 | 2022 | 772 | 0.560 |
Why?
|
| Prospective Studies | 24 | 2023 | 6219 | 0.550 |
Why?
|
| HLA Antigens | 4 | 2011 | 225 | 0.540 |
Why?
|
| Delivery of Health Care | 3 | 2015 | 833 | 0.540 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2016 | 9 | 0.530 |
Why?
|
| Referral and Consultation | 3 | 2021 | 632 | 0.530 |
Why?
|
| Bayes Theorem | 2 | 2017 | 329 | 0.530 |
Why?
|
| Clinical Trials as Topic | 8 | 2023 | 931 | 0.530 |
Why?
|
| Incidence | 15 | 2021 | 2313 | 0.530 |
Why?
|
| Logistic Models | 14 | 2017 | 1841 | 0.530 |
Why?
|
| Allografts | 7 | 2021 | 122 | 0.520 |
Why?
|
| Medical Staff, Hospital | 2 | 2013 | 75 | 0.520 |
Why?
|
| Guideline Adherence | 3 | 2019 | 490 | 0.520 |
Why?
|
| Survivors | 2 | 2018 | 411 | 0.510 |
Why?
|
| Models, Biological | 3 | 2017 | 1620 | 0.510 |
Why?
|
| Metabolic Syndrome | 6 | 2018 | 321 | 0.500 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 121 | 0.490 |
Why?
|
| Documentation | 2 | 2013 | 167 | 0.480 |
Why?
|
| Hospital Costs | 1 | 2015 | 104 | 0.480 |
Why?
|
| Heart Valve Diseases | 2 | 2016 | 161 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 1177 | 0.480 |
Why?
|
| Obesity | 5 | 2016 | 2508 | 0.480 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 616 | 0.470 |
Why?
|
| Age Factors | 13 | 2021 | 2894 | 0.460 |
Why?
|
| Comorbidity | 14 | 2023 | 1448 | 0.460 |
Why?
|
| Models, Theoretical | 2 | 2023 | 515 | 0.460 |
Why?
|
| Testosterone | 2 | 2014 | 343 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 4 | 2024 | 180 | 0.440 |
Why?
|
| Odds Ratio | 9 | 2019 | 953 | 0.440 |
Why?
|
| Dog Diseases | 2 | 2010 | 41 | 0.430 |
Why?
|
| Hemolysis | 4 | 2017 | 146 | 0.430 |
Why?
|
| Methylprednisolone | 1 | 2013 | 81 | 0.420 |
Why?
|
| Intensive Care Units | 3 | 2013 | 617 | 0.420 |
Why?
|
| Health Care Rationing | 2 | 2010 | 45 | 0.420 |
Why?
|
| Insurance, Health | 5 | 2018 | 244 | 0.420 |
Why?
|
| Inpatients | 2 | 2015 | 380 | 0.420 |
Why?
|
| Histocompatibility Testing | 2 | 2011 | 116 | 0.420 |
Why?
|
| Quality of Health Care | 6 | 2023 | 573 | 0.420 |
Why?
|
| Nephrologists | 2 | 2023 | 12 | 0.420 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 1430 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 253 | 0.410 |
Why?
|
| Blood Specimen Collection | 3 | 2017 | 31 | 0.410 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 91 | 0.410 |
Why?
|
| Patient Participation | 3 | 2015 | 359 | 0.410 |
Why?
|
| Antilymphocyte Serum | 5 | 2020 | 60 | 0.410 |
Why?
|
| Uric Acid | 5 | 2018 | 148 | 0.400 |
Why?
|
| Myasthenia Gravis | 2 | 2022 | 18 | 0.400 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 181 | 0.400 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 63 | 0.390 |
Why?
|
| Brain Ischemia | 3 | 2020 | 299 | 0.390 |
Why?
|
| Internship and Residency | 3 | 2021 | 926 | 0.380 |
Why?
|
| Community Health Services | 1 | 2013 | 212 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 1214 | 0.380 |
Why?
|
| Health Status Indicators | 1 | 2012 | 156 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 1262 | 0.370 |
Why?
|
| Azathioprine | 2 | 2020 | 49 | 0.370 |
Why?
|
| Creatinine | 9 | 2023 | 425 | 0.370 |
Why?
|
| Histocompatibility | 2 | 2017 | 26 | 0.370 |
Why?
|
| Cat Diseases | 1 | 2010 | 13 | 0.360 |
Why?
|
| Predictive Value of Tests | 9 | 2022 | 1796 | 0.360 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 122 | 0.360 |
Why?
|
| Adipose Tissue | 1 | 2014 | 539 | 0.360 |
Why?
|
| Policy | 2 | 2023 | 137 | 0.360 |
Why?
|
| Government Regulation | 1 | 2010 | 46 | 0.350 |
Why?
|
| Laparotomy | 1 | 2010 | 103 | 0.350 |
Why?
|
| Frailty | 2 | 2023 | 115 | 0.340 |
Why?
|
| Models, Statistical | 6 | 2022 | 599 | 0.340 |
Why?
|
| Stroke | 4 | 2020 | 1022 | 0.340 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 750 | 0.330 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 671 | 0.330 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 122 | 0.330 |
Why?
|
| Motor Activity | 1 | 2014 | 640 | 0.330 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 30 | 0.330 |
Why?
|
| Antibodies | 3 | 2022 | 371 | 0.330 |
Why?
|
| Syphilis | 2 | 2022 | 26 | 0.330 |
Why?
|
| Apolipoprotein L1 | 2 | 2021 | 12 | 0.330 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 4408 | 0.330 |
Why?
|
| Lithotripsy | 2 | 2019 | 40 | 0.320 |
Why?
|
| Calcineurin Inhibitors | 2 | 2008 | 58 | 0.320 |
Why?
|
| Ureter | 2 | 2019 | 31 | 0.320 |
Why?
|
| Steroids | 1 | 2009 | 144 | 0.320 |
Why?
|
| Sirolimus | 6 | 2014 | 181 | 0.320 |
Why?
|
| Research | 2 | 2010 | 394 | 0.310 |
Why?
|
| Medicaid | 2 | 2009 | 406 | 0.310 |
Why?
|
| Lung | 2 | 2022 | 3559 | 0.310 |
Why?
|
| Risk | 5 | 2019 | 812 | 0.310 |
Why?
|
| Body Weight | 2 | 2009 | 869 | 0.300 |
Why?
|
| Severity of Illness Index | 11 | 2023 | 2538 | 0.300 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 766 | 0.300 |
Why?
|
| Overweight | 1 | 2012 | 471 | 0.300 |
Why?
|
| Disease Progression | 10 | 2021 | 2380 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2017 | 520 | 0.300 |
Why?
|
| Hypertension | 6 | 2017 | 1056 | 0.290 |
Why?
|
| Veterans | 1 | 2018 | 1249 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2094 | 0.280 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 414 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2017 | 663 | 0.270 |
Why?
|
| Databases, Factual | 9 | 2022 | 1125 | 0.270 |
Why?
|
| Child | 13 | 2023 | 18412 | 0.270 |
Why?
|
| Laparoscopy | 1 | 2010 | 398 | 0.270 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2021 | 222 | 0.260 |
Why?
|
| Emigrants and Immigrants | 1 | 2007 | 107 | 0.260 |
Why?
|
| Certification | 2 | 2017 | 89 | 0.250 |
Why?
|
| Transplantation, Homologous | 6 | 2018 | 377 | 0.250 |
Why?
|
| Quality of Life | 5 | 2022 | 2353 | 0.250 |
Why?
|
| Patient Navigation | 2 | 2017 | 64 | 0.250 |
Why?
|
| Kidney Function Tests | 4 | 2016 | 140 | 0.240 |
Why?
|
| Sex Distribution | 2 | 2017 | 337 | 0.240 |
Why?
|
| Perioperative Period | 2 | 2016 | 49 | 0.240 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 1078 | 0.240 |
Why?
|
| Perfusion | 1 | 2005 | 148 | 0.240 |
Why?
|
| Viremia | 3 | 2014 | 122 | 0.240 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 327 | 0.240 |
Why?
|
| Chi-Square Distribution | 7 | 2016 | 493 | 0.230 |
Why?
|
| Fructose | 2 | 2018 | 100 | 0.230 |
Why?
|
| Death | 2 | 2020 | 107 | 0.230 |
Why?
|
| Research Design | 2 | 2017 | 928 | 0.230 |
Why?
|
| Blood Pressure | 4 | 2019 | 1538 | 0.230 |
Why?
|
| Sex Factors | 6 | 2021 | 1715 | 0.220 |
Why?
|
| Insurance Coverage | 3 | 2016 | 200 | 0.220 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 268 | 0.220 |
Why?
|
| Waist Circumference | 2 | 2014 | 122 | 0.210 |
Why?
|
| Ureteroscopy | 2 | 2019 | 16 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 1183 | 0.210 |
Why?
|
| Ambulatory Care Facilities | 3 | 2017 | 213 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2023 | 97 | 0.210 |
Why?
|
| Transplantation Conditioning | 3 | 2009 | 151 | 0.210 |
Why?
|
| Pandemics | 2 | 2021 | 1317 | 0.210 |
Why?
|
| Diabetic Nephropathies | 3 | 2017 | 234 | 0.200 |
Why?
|
| Child, Preschool | 6 | 2021 | 9114 | 0.200 |
Why?
|
| Chlamydia | 1 | 2022 | 10 | 0.200 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 680 | 0.200 |
Why?
|
| Hospital Charges | 2 | 2019 | 39 | 0.200 |
Why?
|
| Brain Death | 2 | 2020 | 31 | 0.190 |
Why?
|
| Motivation | 2 | 2016 | 494 | 0.190 |
Why?
|
| Defibrillators, Implantable | 2 | 2015 | 286 | 0.190 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 7 | 0.190 |
Why?
|
| Urologic Diseases | 2 | 2019 | 35 | 0.190 |
Why?
|
| Stomach Diseases | 1 | 2021 | 19 | 0.190 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 65 | 0.190 |
Why?
|
| Alemtuzumab | 3 | 2017 | 12 | 0.190 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 70 | 0.190 |
Why?
|
| Gonorrhea | 1 | 2022 | 54 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1394 | 0.190 |
Why?
|
| Histamine H2 Antagonists | 1 | 2021 | 26 | 0.190 |
Why?
|
| Liver | 3 | 2023 | 1637 | 0.180 |
Why?
|
| Proteinuria | 1 | 2021 | 77 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2022 | 168 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 321 | 0.180 |
Why?
|
| Podocytes | 1 | 2021 | 44 | 0.180 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 96 | 0.180 |
Why?
|
| Biomarkers | 7 | 2020 | 3408 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 241 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 155 | 0.170 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 467 | 0.170 |
Why?
|
| Abdominal Fat | 1 | 2020 | 39 | 0.170 |
Why?
|
| Acute Disease | 5 | 2017 | 911 | 0.170 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2019 | 3 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 102 | 0.170 |
Why?
|
| Insurance Benefits | 1 | 2019 | 11 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 69 | 0.170 |
Why?
|
| Isoantibodies | 3 | 2011 | 57 | 0.170 |
Why?
|
| Income | 3 | 2023 | 167 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2010 | 1211 | 0.170 |
Why?
|
| Chronic Disease | 8 | 2017 | 1578 | 0.170 |
Why?
|
| Machine Learning | 1 | 2023 | 316 | 0.170 |
Why?
|
| Viral Load | 3 | 2016 | 405 | 0.170 |
Why?
|
| Health Facility Administration | 2 | 2010 | 6 | 0.170 |
Why?
|
| Thrombectomy | 1 | 2019 | 51 | 0.170 |
Why?
|
| Magnesium | 1 | 2020 | 145 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 165 | 0.160 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 13 | 0.160 |
Why?
|
| Triticum | 1 | 2019 | 9 | 0.160 |
Why?
|
| Myocardial Revascularization | 2 | 2016 | 67 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 177 | 0.160 |
Why?
|
| Decision Trees | 1 | 2019 | 81 | 0.160 |
Why?
|
| Costs and Cost Analysis | 3 | 2016 | 196 | 0.160 |
Why?
|
| Internal Medicine | 1 | 2021 | 211 | 0.160 |
Why?
|
| Patient Admission | 1 | 2020 | 176 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 135 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 117 | 0.160 |
Why?
|
| Adiposity | 2 | 2014 | 457 | 0.160 |
Why?
|
| Propensity Score | 5 | 2020 | 224 | 0.160 |
Why?
|
| Stroke Volume | 2 | 2019 | 504 | 0.160 |
Why?
|
| Risk Adjustment | 2 | 2010 | 76 | 0.160 |
Why?
|
| Medical Futility | 1 | 2018 | 20 | 0.160 |
Why?
|
| Patient Transfer | 1 | 2020 | 143 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 913 | 0.150 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 380 | 0.150 |
Why?
|
| Heat-Shock Response | 1 | 2018 | 46 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 187 | 0.150 |
Why?
|
| Biopsy | 4 | 2021 | 1036 | 0.150 |
Why?
|
| Infant | 6 | 2023 | 7961 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 220 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2020 | 381 | 0.150 |
Why?
|
| Employment | 2 | 2016 | 137 | 0.150 |
Why?
|
| Phlebotomy | 1 | 2017 | 12 | 0.150 |
Why?
|
| Vitamin D | 2 | 2011 | 341 | 0.150 |
Why?
|
| Hypotension | 1 | 2019 | 116 | 0.150 |
Why?
|
| Gout Suppressants | 1 | 2017 | 20 | 0.150 |
Why?
|
| Hypernatremia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Fatigue | 1 | 2019 | 294 | 0.140 |
Why?
|
| Hyperuricemia | 1 | 2017 | 43 | 0.140 |
Why?
|
| Aftercare | 1 | 2019 | 186 | 0.140 |
Why?
|
| Diabetes Complications | 3 | 2009 | 211 | 0.140 |
Why?
|
| Dendritic Cells | 3 | 2005 | 435 | 0.140 |
Why?
|
| Health Records, Personal | 1 | 2017 | 24 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 183 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2021 | 292 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 121 | 0.140 |
Why?
|
| Case-Control Studies | 6 | 2022 | 3003 | 0.140 |
Why?
|
| Body Image | 1 | 2018 | 68 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2017 | 37 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 376 | 0.140 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 771 | 0.140 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 4622 | 0.140 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 144 | 0.140 |
Why?
|
| Treponema pallidum | 1 | 2016 | 7 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 152 | 0.140 |
Why?
|
| Financing, Personal | 1 | 2016 | 25 | 0.130 |
Why?
|
| Laboratories, Hospital | 1 | 2016 | 13 | 0.130 |
Why?
|
| Parental Leave | 1 | 2016 | 17 | 0.130 |
Why?
|
| Graft vs Host Disease | 4 | 2008 | 212 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 167 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 284 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 182 | 0.130 |
Why?
|
| Contrast Media | 1 | 2018 | 345 | 0.130 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 50 | 0.130 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 109 | 0.130 |
Why?
|
| Affect | 1 | 2018 | 246 | 0.130 |
Why?
|
| Length of Stay | 3 | 2016 | 962 | 0.130 |
Why?
|
| Hospitals, General | 1 | 2015 | 19 | 0.130 |
Why?
|
| HIV Infections | 2 | 2022 | 2469 | 0.130 |
Why?
|
| Stents | 1 | 2019 | 475 | 0.130 |
Why?
|
| Hypokalemia | 1 | 2015 | 24 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 155 | 0.120 |
Why?
|
| Palliative Care | 1 | 2021 | 642 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 272 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 56 | 0.120 |
Why?
|
| Fear | 1 | 2018 | 293 | 0.120 |
Why?
|
| Hyperkalemia | 1 | 2015 | 26 | 0.120 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 132 | 0.120 |
Why?
|
| Regression Analysis | 3 | 2014 | 944 | 0.120 |
Why?
|
| Algorithms | 3 | 2022 | 1468 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 196 | 0.120 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 951 | 0.120 |
Why?
|
| Catheters | 1 | 2015 | 63 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 561 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2015 | 104 | 0.120 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 77 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 413 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 681 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 235 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 239 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 322 | 0.120 |
Why?
|
| Equipment Design | 1 | 2016 | 508 | 0.120 |
Why?
|
| Intention | 2 | 2015 | 144 | 0.120 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 522 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 544 | 0.120 |
Why?
|
| Chelating Agents | 1 | 2014 | 65 | 0.110 |
Why?
|
| Health Status | 3 | 2021 | 722 | 0.110 |
Why?
|
| Hemodialysis, Home | 1 | 2014 | 8 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 160 | 0.110 |
Why?
|
| Information Services | 1 | 2014 | 44 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2015 | 337 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 70 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2016 | 278 | 0.110 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 33 | 0.110 |
Why?
|
| Selection Bias | 2 | 2010 | 33 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 172 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2015 | 155 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 921 | 0.110 |
Why?
|
| Public Health | 1 | 2017 | 433 | 0.110 |
Why?
|
| Florida | 2 | 2011 | 73 | 0.110 |
Why?
|
| Phosphates | 1 | 2014 | 159 | 0.110 |
Why?
|
| House Calls | 1 | 2014 | 115 | 0.110 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 64 | 0.110 |
Why?
|
| Patients | 1 | 2015 | 163 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 60 | 0.110 |
Why?
|
| Urologic Surgical Procedures | 1 | 2014 | 94 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2019 | 701 | 0.110 |
Why?
|
| Receptors, KIR | 1 | 2014 | 92 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 993 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 279 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2016 | 368 | 0.110 |
Why?
|
| Program Development | 1 | 2015 | 341 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 298 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 467 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 12 | 0.100 |
Why?
|
| Dogs | 2 | 2010 | 334 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 517 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 143 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 84 | 0.100 |
Why?
|
| Hypoalbuminemia | 1 | 2012 | 27 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2763 | 0.100 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 975 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2020 | 1072 | 0.100 |
Why?
|
| Whole-Body Irradiation | 2 | 2009 | 73 | 0.100 |
Why?
|
| Skin | 1 | 2016 | 655 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2017 | 870 | 0.100 |
Why?
|
| Anthropometry | 1 | 2012 | 182 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 87 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 358 | 0.100 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 900 | 0.100 |
Why?
|
| Quality Control | 2 | 2016 | 144 | 0.100 |
Why?
|
| Bicarbonates | 1 | 2011 | 41 | 0.100 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 30 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 2012 | 138 | 0.090 |
Why?
|
| Hypophosphatemia | 1 | 2011 | 15 | 0.090 |
Why?
|
| Inflammation | 2 | 2020 | 2478 | 0.090 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 116 | 0.090 |
Why?
|
| Urban Population | 1 | 2013 | 397 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 444 | 0.090 |
Why?
|
| Caloric Restriction | 1 | 2012 | 90 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 209 | 0.090 |
Why?
|
| Cyclosporine | 3 | 2011 | 161 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 172 | 0.090 |
Why?
|
| Mothers | 1 | 2016 | 651 | 0.090 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2010 | 16 | 0.090 |
Why?
|
| Renin | 1 | 2010 | 31 | 0.090 |
Why?
|
| Glomerulonephritis | 1 | 2010 | 45 | 0.090 |
Why?
|
| Physical Phenomena | 1 | 2010 | 12 | 0.090 |
Why?
|
| Cats | 1 | 2010 | 193 | 0.090 |
Why?
|
| Virus Activation | 2 | 2013 | 78 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 2387 | 0.090 |
Why?
|
| Rural Population | 1 | 2013 | 446 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2009 | 21 | 0.090 |
Why?
|
| Polycythemia | 1 | 2010 | 23 | 0.090 |
Why?
|
| Allopurinol | 1 | 2009 | 53 | 0.080 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2009 | 5 | 0.080 |
Why?
|
| Heart Block | 1 | 2009 | 38 | 0.080 |
Why?
|
| Myeloablative Agonists | 1 | 2009 | 21 | 0.080 |
Why?
|
| National Health Programs | 1 | 2009 | 20 | 0.080 |
Why?
|
| Busulfan | 1 | 2009 | 14 | 0.080 |
Why?
|
| Vidarabine | 1 | 2009 | 26 | 0.080 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 29 | 0.080 |
Why?
|
| Organizational Innovation | 1 | 2010 | 132 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 158 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 70 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 32 | 0.080 |
Why?
|
| Energy Intake | 1 | 2012 | 427 | 0.080 |
Why?
|
| Health Behavior | 1 | 2015 | 704 | 0.080 |
Why?
|
| Topography, Medical | 1 | 2009 | 12 | 0.080 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2022 | 52 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 81 | 0.080 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 578 | 0.080 |
Why?
|
| United Kingdom | 1 | 2009 | 226 | 0.080 |
Why?
|
| Prevalence | 4 | 2020 | 2251 | 0.080 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 378 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 106 | 0.080 |
Why?
|
| Recurrence | 4 | 2021 | 935 | 0.080 |
Why?
|
| Models, Economic | 1 | 2008 | 48 | 0.080 |
Why?
|
| Minority Groups | 1 | 2010 | 227 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2014 | 3252 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 10 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 290 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2009 | 5045 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1121 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2021 | 539 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2009 | 293 | 0.070 |
Why?
|
| Patient Care | 1 | 2007 | 101 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2006 | 20 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 645 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2006 | 38 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1737 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 76 | 0.060 |
Why?
|
| Transportation | 2 | 2016 | 44 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 342 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 585 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 54 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 110 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2007 | 255 | 0.060 |
Why?
|
| Leukocytes | 1 | 2006 | 276 | 0.060 |
Why?
|
| Consensus | 2 | 2018 | 537 | 0.060 |
Why?
|
| Antigens | 1 | 2006 | 318 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 149 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2005 | 92 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2006 | 218 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2004 | 68 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 248 | 0.060 |
Why?
|
| Diet | 1 | 2010 | 1080 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2024 | 60 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 209 | 0.050 |
Why?
|
| Arterial Pressure | 2 | 2014 | 99 | 0.050 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 195 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2020 | 1226 | 0.050 |
Why?
|
| Lithium | 1 | 2023 | 36 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1728 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 64 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1879 | 0.050 |
Why?
|
| Health Personnel | 1 | 2008 | 574 | 0.050 |
Why?
|
| Phosphorus | 2 | 2014 | 82 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 95 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 412 | 0.050 |
Why?
|
| Microscopy | 1 | 2023 | 125 | 0.050 |
Why?
|
| HLA-DQ Antigens | 1 | 2022 | 174 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 183 | 0.050 |
Why?
|
| Exercise | 1 | 2012 | 1644 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2019 | 574 | 0.050 |
Why?
|
| Relative Value Scales | 1 | 2021 | 5 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2021 | 10 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 89 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2022 | 274 | 0.050 |
Why?
|
| Workload | 1 | 2022 | 132 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2021 | 126 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 37 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 208 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 334 | 0.040 |
Why?
|
| ROC Curve | 1 | 2022 | 442 | 0.040 |
Why?
|
| Databases as Topic | 3 | 2005 | 63 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 620 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1139 | 0.040 |
Why?
|
| Clinical Clerkship | 1 | 2021 | 72 | 0.040 |
Why?
|
| United States Public Health Service | 1 | 2019 | 8 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 171 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 229 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2005 | 685 | 0.040 |
Why?
|
| Probability | 1 | 2020 | 289 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 156 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 872 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 66 | 0.040 |
Why?
|
| Calcium Oxalate | 1 | 2018 | 5 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 25 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 90 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 289 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 191 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 198 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 287 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 594 | 0.040 |
Why?
|
| Terminal Care | 1 | 2021 | 213 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 768 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 40 | 0.040 |
Why?
|
| Lipids | 2 | 2013 | 580 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 7 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2014 | 1373 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2285 | 0.040 |
Why?
|
| Hematologic Neoplasms | 2 | 2009 | 137 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 83 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 743 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 663 | 0.030 |
Why?
|
| Silver Staining | 1 | 2016 | 17 | 0.030 |
Why?
|
| Calcium | 2 | 2014 | 1108 | 0.030 |
Why?
|
| Animals | 3 | 2017 | 31698 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 304 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 553 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 134 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 1760 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 257 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 733 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 87 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 195 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 1004 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 76 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2019 | 398 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 46 | 0.030 |
Why?
|
| Potassium | 1 | 2015 | 128 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 105 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 71 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2015 | 106 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 86 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2015 | 62 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 179 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 114 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 57 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 331 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2014 | 16 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 429 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2014 | 63 | 0.030 |
Why?
|
| Cell Count | 2 | 2005 | 303 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2014 | 75 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2015 | 285 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2016 | 348 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 121 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 243 | 0.030 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 10 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 434 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 233 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 10 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2012 | 25 | 0.030 |
Why?
|
| Medical Audit | 1 | 2013 | 75 | 0.030 |
Why?
|
| Health Literacy | 1 | 2015 | 164 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 582 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2013 | 1826 | 0.030 |
Why?
|
| Health Services | 1 | 2013 | 103 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 1003 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2014 | 315 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2005 | 1083 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 358 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 154 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 430 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 90 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 121 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 96 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 934 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 529 | 0.020 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 2 | 0.020 |
Why?
|
| Family | 1 | 2013 | 589 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2011 | 101 | 0.020 |
Why?
|
| Aneurysm | 1 | 2009 | 29 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 162 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 61 | 0.020 |
Why?
|
| Communication | 1 | 2015 | 744 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 249 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 718 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 94 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 442 | 0.020 |
Why?
|
| Diethylamines | 1 | 2008 | 2 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1381 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 35 | 0.020 |
Why?
|
| Blood Cells | 1 | 2008 | 38 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 133 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 240 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 233 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 497 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 287 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2017 | 1512 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 49 | 0.020 |
Why?
|
| HLA-DP Antigens | 1 | 2007 | 32 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 319 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1842 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 460 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 772 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 560 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2796 | 0.020 |
Why?
|
| Critical Care | 1 | 2009 | 476 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 5518 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2009 | 712 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 2097 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 33 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 770 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 274 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 749 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2005 | 219 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 520 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 546 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 2078 | 0.010 |
Why?
|